APA (7th ed.) Citation

Huang, X., Ding, Q., Guo, H., Gong, Y., Zhao, J., Zhao, M., . . . Huo, L. (2021). Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Human pathology, 108, 42-50. https://doi.org/10.1016/j.humpath.2020.11.004

Chicago Style (17th ed.) Citation

Huang, Xiao, et al. "Comparison of Three FDA-approved Diagnostic Immunohistochemistry Assays of PD-L1 in Triple-negative Breast Carcinoma." Human Pathology 108 (2021): 42-50. https://doi.org/10.1016/j.humpath.2020.11.004.

MLA (9th ed.) Citation

Huang, Xiao, et al. "Comparison of Three FDA-approved Diagnostic Immunohistochemistry Assays of PD-L1 in Triple-negative Breast Carcinoma." Human Pathology, vol. 108, 2021, pp. 42-50, https://doi.org/10.1016/j.humpath.2020.11.004.